SUPERNUS PHARMACEUTICALS ($SUPN) posted quarterly earnings results on Tuesday, May 6th. The company reported earnings of $0.42 per share, beating estimates of $0.38 by $0.04. The company also reported revenue of $149,820,000, missing estimates of $149,874,720 by $-54,720.
You can see Quiver Quantitative's $SUPN stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
SUPERNUS PHARMACEUTICALS Insider Trading Activity
SUPERNUS PHARMACEUTICALS insiders have traded $SUPN stock on the open market 13 times in the past 6 months. Of those trades, 0 have been purchases and 13 have been sales.
Here’s a breakdown of recent trading of $SUPN stock by insiders over the last 6 months:
- JACK A. KHATTAR (President, CEO) has made 0 purchases and 2 sales selling 250,000 shares for an estimated $9,121,250.
- PADMANABH P. BHATT (Sr. VP of IP, CSO) has made 0 purchases and 5 sales selling 34,245 shares for an estimated $1,294,349.
- GEORGES GEMAYEL has made 0 purchases and 2 sales selling 25,000 shares for an estimated $912,048.
- FRANK MOTTOLA (SVP, Quality, GMP, Ops, IT) sold 15,000 shares for an estimated $554,700
- CHARLES W III NEWHALL sold 10,700 shares for an estimated $387,768
- FREDERICK M. HUDSON sold 8,722 shares for an estimated $316,434
- JONATHAN RUBIN (SVP, Chief Medical Officer) sold 927 shares for an estimated $36,292
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
SUPERNUS PHARMACEUTICALS Hedge Fund Activity
We have seen 129 institutional investors add shares of SUPERNUS PHARMACEUTICALS stock to their portfolio, and 130 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- PACER ADVISORS, INC. removed 1,193,828 shares (-74.7%) from their portfolio in Q1 2025, for an estimated $39,097,867
- BLACKROCK, INC. removed 313,384 shares (-3.1%) from their portfolio in Q1 2025, for an estimated $10,263,326
- ARMISTICE CAPITAL, LLC removed 260,000 shares (-5.1%) from their portfolio in Q4 2024, for an estimated $9,401,600
- POLAR CAPITAL HOLDINGS PLC removed 250,000 shares (-12.9%) from their portfolio in Q4 2024, for an estimated $9,040,000
- WOODLINE PARTNERS LP added 235,257 shares (+124.8%) to their portfolio in Q4 2024, for an estimated $8,506,893
- MILLENNIUM MANAGEMENT LLC removed 222,273 shares (-87.9%) from their portfolio in Q4 2024, for an estimated $8,037,391
- SCHRODER INVESTMENT MANAGEMENT GROUP removed 216,640 shares (-42.0%) from their portfolio in Q4 2024, for an estimated $7,833,702
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
SUPERNUS PHARMACEUTICALS Congressional Stock Trading
Members of Congress have traded $SUPN stock 1 times in the past 6 months. Of those trades, 1 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $SUPN stock by members of Congress over the last 6 months:
- REPRESENTATIVE GILBERT RAY CISNEROS, JR. purchased up to $15,000 on 03/24.
To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard.
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
